March 27, 2025 SARC Seeks Medical Monitor to Support Sarcoma Clinical Trials Position is ideal for physicians with experience in oncology clinical trials who are dedicated to advancing sarcoma research. Read more
August 20, 2024 SARC 044 Open for Enrollment SARC’s newest clinical trial, SARC044, is now open for enrollment! This trial aims to enroll patients with GIST who have previously progressed on sunitinib. Read more
June 13, 2024 SARC037 Progress Announced at ASCO 2024 Dr. Patrick Grohar presented the SARC037 findings at ASCO 2024. The results suggest that EWS::FLI1 is a target for Ewing sarcoma and the combination of trabectedin/irinotecan is active in treatment-refractory Ewing sarcoma patients. Read more
June 10, 2024 Sarcoma Centers Spotlight In this SARC Sarcoma Centers Spotlight we feature Jessica Lowenstein, M.S., DABR, a medical physicist, and Hannah Nguyen, M.S. (RS), CMD, a medical dosimetrist, both of whom work at RQA Lab and IROC Houston located at MD Anderson Cancer Center. Read more
June 7, 2024 SU2C-SARC032 Positive Results Revealed at ASCO Dr. David Kirsch unveiled the SU2C-SARC032 findings at ASCO 2024. The results indicate that adding pembro decreases the risk of cancer recurrence by 43% two years after treatment. Read more
May 24, 2024 Advancements in GIST Research to be Announced at ASCO SARC, alongside sarcoma research leaders like Cogent Biosciences, Dana Farber Cancer Institute and The Life Raft Group, is committed to collaborating to advance treatment options for GIST patients. Read more
April 23, 2024 SARC-Sponsored Studies Selected for Oral Presentations at ASCO SARC032 and SARC037 to be presented at ASCO 2024. Read more
July 14, 2023 SARC037 is Open and Accruing In a rare disease as Ewing sarcoma, we recognize we need to work together to complete important studies like this. Read more
January 3, 2023 proviDING hope for patients with osteosarcoma Derek Fadness was only the second patient in the nation to join this clinical trial. Read his remarkable story. Read more
May 9, 2022 SARC032 EXPANDED SU2C has made additional funds available for SARC032 so that we can increase the sample size and power of this randomized, ongoing trial from 102 to 126 evaluable patients. SARC032 … Read more